Medical Treatment With or Without Transcatheter Patent Foramen Ovale Closure

NAActive, not recruitingINTERVENTIONAL
Enrollment

714

Participants

Timeline

Start Date

December 1, 2023

Primary Completion Date

October 1, 2026

Study Completion Date

October 1, 2036

Conditions
Patent Foramen OvaleCryptogenic StrokeOlder PatientsMedical TreatmentRecurrent Stroke
Interventions
PROCEDURE

Transcatheter PFO closure

"Transcatheter PFO closure procedure will be performed according to the standards and experience of each participating center. Any approved PFO occluder device will be allowed in the study.~Patients will also receive antithrombotic agents (single antiplatelet treatment ), and modifiable vascular risk factors (dyslipidemia, hypertension, diabetes) according to stroke prevention guidelines. The type of antithrombotic therapy will be left to the discretion of the physician responsible for the patient."

DRUG

Optimal medical treatment

Patients will receive antithrombotic agents (single antiplatelet treatment ), and modifiable vascular risk factors (dyslipidemia, hypertension, diabetes) according to stroke prevention guidelines. The type of antithrombotic therapy will be left to the discretion of the physician responsible for the patient.

Trial Locations (1)

G1V 4G5

IUCPQ-UL, Québec

All Listed Sponsors
lead

Josep Rodes-Cabau

OTHER

NCT05907694 - Medical Treatment With or Without Transcatheter Patent Foramen Ovale Closure | Biotech Hunter | Biotech Hunter